Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program Kirchner RM; Abbott JDVasc Health Risk Manag 2009[]; 5 (ä): 1089-97Drug-eluting stents (DES) have had a major impact in interventional cardiology. Compared to bare metal stents, they significantly reduce restenosis and the need for target vessel revascularization. Four DES are available in the US, the first-generation sirolimus-eluting (Cypher((R))) and paclitaxel-eluting (Taxus((R))) stents and later approved second-generation everolimus-eluting (Xience V((R))) and zotarolimus-eluting (Endeavor((R))) stents. The Xience V stent was approved on the basis of clinical efficacy and safety data from 3 studies in the SPIRIT clinical trial program. Within this trial series, the Xience V was superior to its bare metal stent counterpart, the Vision(R) stent, and noninferior to the paclitaxel-eluting stent for target vessel failure at 9 months. This review provides a comprehensive assessment of the data derived from both the pre- and post-approval randomized controlled trials and registry studies of Xience V that comprise the SPIRIT clinical trial program including recently published mid-term outcomes. The implications of the results in terms of interventional practice will be discussed.|*Drug-Eluting Stents[MESH]|Angioplasty, Balloon, Coronary/adverse effects/*instrumentation/mortality[MESH]|Cardiovascular Agents/*administration & dosage[MESH]|Everolimus[MESH]|Evidence-Based Medicine[MESH]|Female[MESH]|Humans[MESH]|Male[MESH]|Multicenter Studies as Topic[MESH]|Prospective Studies[MESH]|Prosthesis Design[MESH]|Randomized Controlled Trials as Topic[MESH]|Registries[MESH]|Sirolimus/administration & dosage/*analogs & derivatives[MESH]|Time Factors[MESH]|Treatment Outcome[MESH] |
